Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5

Benzinga · 1d ago
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.